Parabolic Drugs surges on receiving European GMP Certifications

23 May 2014 Evaluate

Parabolic Drugs is currently trading at Rs 7.93, up by 0.37 points or 4.89% from its previous closing of Rs 7.56 on the BSE.

The scrip opened at Rs 7.93 and has touched a high and low of Rs 7.93 and Rs 7.90 respectively. So far 38961 shares were traded on the counter.

The BSE group 'T' stock of face value Rs 10 has touched a 52 week high of Rs 8.49 on 06-Jan-2014 and a 52 week low of Rs 3.39 on 07-Aug-2013.

Last one week high and low of the scrip stood at Rs 7.56 and Rs. 5.85 respectively. The current market cap of the company is Rs 49.08 crore.

The promoters holding in the company stood at 38.31% while Institutions and Non-Institutions held 15.95% and 45.74% respectively.

Parabolic Drugs has received European GMP Certifications for its Works Site located at Derabassi for manufacture of Cephalosporin products and at Lalru for manufacture of Non-beta Lactams products.

Parabolic Drugs (PDL) has commenced its commercial operations in 1998 with contract manufacturing of APIs and API intermediates for sales in India and abroad (including regulated markets). PDL presently has four facilities comprising of three manufacturing plants, viz, Derabassi and Chachrauli (both Punjab) and Panchkula and an R&D centre at Barwala (both Haryana).

Parabolic Drugs Share Price

1.05 0.00 (0.00%)
25-Jan-2021 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.